dr. tyna moore glp-1 I was recently joined by and Calley Means on The Doctor's Farmacy for a controversial discussion of agonists like Ozempic, weighing the pros and cons of these peptides 2360: What You Need to

(2022) 12(9):e060668

"GIP and GLP-1, the Two Incretin Hormones: Similarities and Differences"

As more patients use glucagon-like peptide-1 (GLP-1) receptor agonists for weight loss and to manage their type 2 diabetes, reports of these drugs effects on hair loss have emerged, including a retrospective cohort study 2 and a disproportionality analysis 3 of the U.S

Both agonists affect cancer in vitro by decreasing the proliferation and metabolic pathways at varying concentrations

There has been a marked increase in the use of these medications since they were first approved for weight loss in 2014, particularly following the approval of Wegovy in 2021 and Zepbound in 2022

The dosage may be gradually increased over time, depending on how well the medication is tolerated and the desired weight loss goals